RT Journal Article
SR Electronic
T1 Use of B-Cell–Depleting Therapy in Women of Childbearing Potential With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 154
OP 163
DO 10.1212/CPJ.0000000000001147
VO 12
IS 2
A1 Alexandra Galati
A1 Thomas McElrath
A1 Riley Bove
YR 2022
UL http://cp.neurology.org/content/12/2/154.abstract
AB Purpose of Review There is considerable heterogeneity in the use of B-cell depletion in women of childbearing age, likely driven at least in part by the discrepancy between the product labels and what is known about the physiology of IgG1, including breastmilk and placental transfer.Recent Findings We provide practical considerations on the use of this medication class in women of childbearing potential. We discuss prepregnancy planning including vaccinations, safety of B-cell depletion during pregnancy, and postpartum considerations including breastfeeding.Summary B-cell–depleting monoclonal antibodies have shown to be effective for prepregnancy and postpartum prevention of inflammatory activity in MS and neuromyelitis optica spectrum disorder. B-cell–depleting therapies are large IgG1 monoclonal antibodies, which have minimal transfer across the placenta and into breastmilk. Consideration of risks and benefits of these therapies should be considered in counseling women planning pregnancy and postpartum.